SCHEMBL965627

SCHEMBL965627

Oc1c(-c2nnc(Cc3cc(F)cc(F)c3)[nH]2)nc(N2CCCCS2(O)O)c2cccnc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALCA P06881 9/20 0.51
COMT P21964 2/20 0.33
KDM4E B2RXH2 5/20 0.32
L3MBTL1 Q9Y468 4/20 0.32
HTT P42858 4/20 0.32
SMN1; SMN2 Q16637 4/20 0.32
ALOX15 P16050 3/20 0.32
ALOX12 P18054 3/20 0.32
LMNA P02545 3/20 0.32
NPSR1 Q6W5P4 3/20 0.32
NPC1 O15118 2/20 0.32
TP53 P04637 2/20 0.32
HSP90AA1 P07900 2/20 0.32
RAB9A P51151 2/20 0.32
METAP2 P50579 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
MPI P34949 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL968247 0.94 CALCA (0.52) CALCACOMTKDM4EL3MBTL1HTT
SCHEMBL968042 0.93 CALCA (0.50) CALCACOMTKDM4EL3MBTL1HTT
SCHEMBL965626 0.91 CALCA (0.62) CALCACOMTKDM4EL3MBTL1HTT
SCHEMBL966049 0.90 CALCA (0.43) CALCACOMTKDM4EL3MBTL1HTT
SCHEMBL965779 0.90 CALCA (0.48) CALCACOMTKDM4EL3MBTL1HTT
SCHEMBL967390 0.89 CALCA (0.42) CALCACOMTKDM4EL3MBTL1HTT
SCHEMBL966987 0.88 CALCA (0.50) CALCAKDM4EL3MBTL1HTTSMN1; SMN2
SCHEMBL967706 0.88 CALCA (0.41) CALCACOMTKDM4EL3MBTL1HTT
SCHEMBL967789 0.86 CALCA (0.42) CALCAKDM4EL3MBTL1HTTSMN1; SMN2
SCHEMBL965743 0.85 CALCA (0.40) CALCACOMTKDM4EL3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622615-A4 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-02-18 EP claimed
US-20070142365-A1 Naphthyridine integrase inhibitors GSK LLC 2007-06-21 US claimed
EP-1622615-A2 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-02-08 EP claimed
WO-2004101512-A2 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-11-25 WO claimed
US-20110003794-A1 Naphthyridine Integrase Inhibitors GSK LLC 2011-01-06 US disclosed
US-7812016-B2 Naphthyridine integrase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2010-10-12 US disclosed
EP-1622615-A4 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-02-18 EP disclosed
US-20070142365-A1 Naphthyridine integrase inhibitors GSK LLC 2007-06-21 US disclosed
EP-1622615-A2 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-02-08 EP disclosed
WO-2004101512-A2 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003794-A1 Naphthyridine Integrase Inhibitors PCNA, SAMHD1, NTPCR CALCA 4461/4885COMT 1043/4885KDM4E 2029/4885
US-20070142365-A1 Naphthyridine integrase inhibitors PCNA, SAMHD1, NTPCR CALCA 4461/4885COMT 1043/4885KDM4E 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.